High Morbidity and Mortality in HIV-1 Exposed Uninfected (HEU) Infants: The Role of Cytomegalovirus Infection

High Morbidity and Mortality in HIV-1 Exposed Uninfected (HEU) Infants: The Role of Cytomegalovirus Infection

Moraka’s current study is a retrospective cohort study of HIV-exposed uninfected infants and their mothers which involves evaluating the effects of HIV/CMV exposure on infant adverse neurodevelopmental and health outcomes. The samples used in this study are part of the “Effects of HIV and ARV Exposure on Child Health and Neurodevelopment, Botswana,” also known as the “Tshipidi Study,” carried out from 2010 to 2012.  Plasma samples from 18-month old HEU infants are available for testing. Delivery plasma samples from about 500 mothers are also available for analysis. These 18-month samples will be tested for HCMV using HCMV IgG ELISA and maternal samples will be tested for HCMV viral load quantification using the COBAS® AmpliPrep/COBAS® TaqMan® CMV Test using COBAS® AmpliPrep Instrument. The main objectives of this study are:

  1. to explore the effect of congenital CMV infection on health and growth (neurodevelopmental) outcomes on HEU infants;

Hypothesis: Infant CMV sero-status will be correlated with poorer infant neurodevelopmental outcomes. Neurodevelopmental outcomes analysed will include head size, length-for-age, weight for age and psychomotor development among others.

  1. to identify the impact of maternal CMV DNA viremia on adverse pregnancy/delivery and infant health outcomes in infants born to HIV positive mothers;

Hypothesis: Detectable maternal CMV viral load is associated with adverse infant health outcomes